Scalper1 News
Juno Therapeutics soared 46% in Friday’s trading debut, the latest sign of investor demand for a new class of cancer-curing firms and for biotechs overall. Juno (JUNO) raised $265 million late Thursday in its IPO with an initial market capitalization of $2.2 billion, the highest valuation for a biotech IPO in 2014, according to IPO (IPO) ETF manager Renaissance Capital. Juno sold 11 million shares at 24. It initially planned to Scalper1 News
Scalper1 News